- Advertise
- Contact Us
- Editorial Info
- Terms and Conditions
- Privacy Policy
- Do Not Sell My Personal Information
© 2021 MJH Life Sciences™ and Practical Cardiology. All rights reserved.
Heart Disease and Diabetes
The Practical Cardiology™ Heart Disease and Diabetes clinical resource center offers readers the latest in the field of diabetes and cardiovascular disease. With the field of cardiometabolic health becoming a focal point in the fight against cardiovascular disease, this page will host content related to the latest FDA approvals, studies, guideline update, and clinical perspectives from advisory board members.
DAPA-CKD Analysis Suggests Farxiga is Safe, Effective in More Advanced Chronic Kidney Disease
July 24, 2021
Data from a prespecified analysis of DAPA-CKD examining effects of dapagliflozin in patients with stage 4 CKD suggests the impact of the SGLT2 inhibitor in these patients was similar to those seen in the overall trial.
Finerenone (Kerendia) Gets FDA Nod for Chronic Kidney Disease in Type 2 Diabetes
July 13, 2021
With approval on July 9, finerenone became the first nonsteroidal mineralocorticoid receptor antagonist approved by the FDA for treatment of chronic kidney disease associated with type 2 diabetes.
Global Use of SGLT2 inhibitors, GLP-1 RAs is Increasing, But Still in Need of Improvement
July 08, 2021
Insights from the DISCOVER registry were presented at the American Diabetes Association's 81st Scientific Sessions. Check out our Q&A with study presenter Suzanne Arnold, MD, of St. Luke's Mid America Heart Institute.
Finding Room at the Table: Sotagliflozin's Ascent into the Cardiometabolic Spotlight, with Deepak Bhatt, MD, MPH
June 29, 2021
Deepak Bhatt, MD, MPH, reflects on the rapid ascent of sotagliflozin (Zynquista) into the spotlight of clinicians specializing in cardiometabolic health thanks to the success of the phase 3 SCORED and SOLOIST trials.
Adding Finerenone to SGLT2 Inhibitor Could Boost Renoprotective Benefit in Patients with Diabetes
June 29, 2021
An analysis from ADA 2021 suggests the renoprotective benefits of finerenone were consistent irrespective of SGLT2 inhibitor use and those using an SGLT2 inhibitor with finerenone resulted in greater UACR reductions.
Older Diabetes Patients Twice As Likely to Report Preventive Aspirin Use
June 23, 2021
An analysis of contemporary trends related to preventive aspirin use suggests older patients with diabetes were twice as likely to use preventive aspirin as their counterparts without diabetes, with many doing so despite it being considered inappropriate based on new guidance.
Multiple Risk Factors Play Role in Odds of Developing Peripheral Artery Disease in Patients with Type 2 Diabetes
June 01, 2021
A systematic review and meta-analysis presented at AACE 2021 sheds light on risk factors associated with increased odds of developing peripheral artery disease among patients with type 2 diabetes.
New Strategies Needed to Address Cardiovascular Risk Trajectory Associated with Prediabetes
May 20, 2021
Analysis of the UK Biobank cohort details a graded increase in risk of cardiovascular and renal events across the glycemic spectrum, including among patients with prediabetes.
Analysis Details SGLT2 Inhibitors Benefit Across Heart Failure Subgroups
May 20, 2021
Hear from Deepak Bhatt, MD, MPH, on a systematic review and meta-analysis of SGLT2 inhibitor trials examining the effects of the class on heart failure across multiple subgroups, including those with preserved ejection fraction.
FIDELIO-DKD Analysis Finds Finerenone Reduces Risk of New-Onset AFib
May 17, 2021
An analysis of FIDELIO-DKD indicates use of finerenone was associated with significant reductions in risk of new-onset atrial fibrillation in patients with type 2 diabetes and chronic kidney disease.